arrow_back Trending Legislation
Share share

Equal Costs for Cancer Drugs: Oral and Intravenous

New rules aim to ensure that insurance plans treat oral cancer medications the same as intravenous ones regarding costs. This means citizens should not pay more for oral anticancer drugs, potentially reducing their treatment expenses. The law is set to take effect from January 1, 2024.
Key points
Insurers cannot charge more for oral cancer drugs than for intravenous ones.
Prohibits increasing cancer treatment costs or reclassifying benefits to raise patient expenses.
The act does not require replacing intravenous drugs with oral ones, nor does it prevent insurers from requiring prior authorization for treatment.
The government will study the impact of these changes on patient out-of-pocket costs.
article Official text account_balance Process page notifications_active Track this Bill
gavel
Status:
Expired
Record your position for audit.
Why does your vote on bills matter?
It creates raw, undeniable proof. Civic Will provides the permanent data to verify the Government's loyalty towards its citizens (explained here). Start recording it now.
Additional Information
Cancer Drug Parity Act of 2023
Print number: HR 6301
Sponsor: Rep. Grothman, Glenn [R-WI-6]
Process start date: 2023-11-08
System Note: Lustra is free, publicly auditable civic infrastructure, with full source code available on GitHub. You are reading sterilized legislative data, processed by our radical neutrality engine to strip political spin and retain factual mechanics. We process only official government data. Original documents remain the authoritative source, always verify them if you can.
Summarized by: gemini-2.5-flash-preview-05-20
Source data: api.congress.gov
AI work logs for this document launch
Summary & Status

Key Questions about Equal Costs for Cancer Drugs: Oral and Intravenous

A structured overview of the legislative process, official sources, status and civic context.

What is the official ID of this bill?

The official print number for this legislation is HR 6301.

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

When did the legislative process begin?

The process officially started on 2023-11-08.

What are the main provisions?

Key points include:

  • Insurers cannot charge more for oral cancer drugs than for intravenous ones.
  • Prohibits increasing cancer treatment costs or reclassifying benefits to raise patient expenses.
  • The act does not require replacing intravenous drugs with oral ones, nor does it prevent insurers from requiring prior authorization for treatment.
  • The government will study the impact of these changes on patient out-of-pocket costs.

What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Rep. Grothman, Glenn [R-WI-6].

What is the latest detailed status?

The latest detailed status is: Referred to the House Committee on Education and the Workforce.

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-25.

Analysis and Potential Impact of HR 6301

We don't know, that is up to you to decide. Summarizing raw data with AI is fundamentally different from predicting socio-economic outcomes. As of 2026, we believe impact assessment strictly requires a human in the loop to verify and judge. Review our public AI processing logs for full transparency, and use Lustra to track active legislation for instant status push notifications.

CATEGORIES

Health